Our study data are now available at the following URL on the AMP T2D Knowledge Portal: <http://www.kp4cd.org/dataset_downloads/t2d>.

Introduction {#sec001}
============

Cigarette smoking and type 2 diabetes (T2D) are both costly burdens on human health in the United States and worldwide \[[@pone.0230815.ref001]--[@pone.0230815.ref004]\]. These public health threats are interrelated: smoking is a dose-dependent risk factor for incident T2D, independent of potential confounders including physical activity and body-mass index (BMI) \[[@pone.0230815.ref005]\]. Moreover, smoking raises fasting glucose (FG) \[[@pone.0230815.ref006], [@pone.0230815.ref007]\] itself a predictor of incident T2D \[[@pone.0230815.ref008]--[@pone.0230815.ref010]\]. Experimental studies point to plausible biologic mechanisms through which smoking may directly cause T2D, such as the impairment of insulin-mediated glucose transport \[[@pone.0230815.ref011]\], insulin sensitivity \[[@pone.0230815.ref012]--[@pone.0230815.ref018]\], and insulin secretion \[[@pone.0230815.ref019]--[@pone.0230815.ref021]\].

Not every individual who smokes develops T2D, and the relationship between smoking and T2D has considerable heterogeneity. This variation suggests the possibility of genetic modifiers of the effect of smoking on T2D risk. Genetic studies of smoking behavior \[[@pone.0230815.ref022]--[@pone.0230815.ref027]\] and T2D and FG \[[@pone.0230815.ref028]--[@pone.0230815.ref036]\] have separately uncovered hundreds of loci associated with these traits, but no genome-wide association study to date has sought genetic loci that modify the relationships among them. We conducted gene-environment-wide interaction studies (GEWIS) to identify potential gene-by-smoking interactions for both T2D risk and FG among 97,773 cohort study participants of European (EA) and African ancestry (AA).

Materials and methods {#sec002}
=====================

Study design overview {#sec003}
---------------------

We conducted two-stage GEWIS analyses to identify potential genotype-smoking interactions for two related traits: incident T2D and baseline FG. Smoking status was dichotomized as individuals who were current or former smokers at baseline (ever smokers) and individuals with no current or past smoking history (never smokers). The discovery stage analyses leveraged data from 5 cohort studies from the Candidate Gene Association Resource (CARe) Consortium. Single-nucleotide polymorphisms (SNPs) that had significant association with a trait in meta-analysis of the discovery cohort data were carried forward for replication in up to 16 cohorts from the Cohorts for Heart & Aging Research in Genomic Epidemiology (CHARGE) Consortium Gene-Lifestyle Interactions Working Group and combined discovery plus replication meta-analysis. The Partners Human Research Committee approved this study.

Cohort descriptions and sample sizes {#sec004}
------------------------------------

In the discovery stage, we analyzed data from five cohorts from the CARe Consortium \[[@pone.0230815.ref037]\]: The Atherosclerosis Risk in Communities Study (ARIC), the Coronary Artery Risk Development in Young Adults Study (CARDIA), the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS), and the Multi-Ethnic Study of Atherosclerosis (MESA) (**[S1 Table](#pone.0230815.s001){ref-type="supplementary-material"}**) \[[@pone.0230815.ref037]\]. The total sample size of these five discovery stage cohorts was 23,189, including 18,365 European American (EA) and 4,824 African American (AA). Among 23,189 CARe participants, 10,120 were never smokers and 13,069 were ever smokers, as assessed at their baseline study examinations. In the replication stage, 74,584 individuals from up to 16 cohorts in the Cohorts for Heart & Aging Research in Genomic Epidemiology (CHARGE) Consortium Gene-Lifestyle Interactions Working Group were included, comprised of 61,397 EA participants and 13,187 AA participants. A total of 40,819 and 33,765 were never and ever smokers, respectively (**[S1 Table](#pone.0230815.s001){ref-type="supplementary-material"}**) \[[@pone.0230815.ref038]\]. All five discovery cohorts contributed data for both traits of interest: incident T2D and baseline glucose. Eight replication cohorts contributed data for the incident T2D analyses, and 15 replication cohorts contributed data for the fasting glucose analyses (**[S1 Table](#pone.0230815.s001){ref-type="supplementary-material"}**). Across the discovery and replication cohorts, there were 4,040 T2D cases and 48,521 controls among EA participants and 717 cases and 7,180 controls among AA participants.

Description of phenotype and covariates {#sec005}
---------------------------------------

We considered two traits: incident T2D and baseline FG. Presence of T2D was defined by any one of the following criteria: 1) FG ≥ 7 mmol/L; 2) on diabetes treatment or HbA1c ≥ 6.5%; 3) 2-hr oral glucose tolerance test ≥11.1 mmol/L; 4) random/non-fasting glucose ≥ 11.1 mmol/L; 5) physician diagnosis of diabetes; or 6) self-reported diabetes (**[S1 Table](#pone.0230815.s001){ref-type="supplementary-material"}**). For the analysis of incident T2D, participants meeting the T2D definition at baseline were excluded. For the remaining participants, time-to-T2D was defined as the time from the date of the baseline examination to the date the T2D case definition was met or, for controls, to the last date of follow-up. For the FG analyses, participants with T2D were excluded, and FG was identified from the baseline measurement taken after a fast of 8 hours or more (**[S1 Table](#pone.0230815.s001){ref-type="supplementary-material"})**.

Genotyping {#sec006}
----------

Participants in the CARe Consortium were genotyped with the custom ITMAT-Broad-CARe (IBC) genotyping array (IBC v2 chip), which contains around 50,000 SNPs across 2,000 loci selected for their relationship to cardiovascular disease and its risk factors. Details about SNP selection criteria and genotyping quality control (QC) procedures have been described \[[@pone.0230815.ref039]\]. Details of the genotyping methods used in the individual CHARGE replication cohorts are presented in **[S1 Table](#pone.0230815.s001){ref-type="supplementary-material"}**.

Cohort-level statistical analysis {#sec007}
---------------------------------

We performed ancestry-stratified analyses for the two traits within each discovery and replication cohort. Smoking-stratified analyses were also conducted separately in each of the four trait-ancestry combinations. In total, we performed four models for each of four trait-ancestry combinations: an interaction model regressing the trait (incident T2D or FG) on the genetic variant, smoking status, and their interaction term (Model 1); a main effect-only model (Model 2); and two smoking-stratified models, regressing incident T2D or FG on the genetic variant predictor in smokers (Model 3) and nonsmokers (Model 4) separately. All models were covariate-adjusted as described below.

We analyzed incident T2D using Cox proportional hazards models and robust sandwich variance estimators. For cohorts with related individuals, each family was treated as a cluster. Models were adjusted for age, BMI, and the genetic principal components associated with incident T2D at *p*\<0.05. Models were not adjusted for sex in the discovery cohorts due to insufficient numbers of incident T2D cases in all sex/ancestry categories; models were conducted with or without sex adjustment in the replication analyses, depending on the sample size of stratified samples.

For baseline FG, we used linear regression for cohorts with independent samples. For cohorts with family structures, we used generalized estimating equations (GEE) to obtain estimates for Model 1, assuming an exchangeable working correlation matrix, since the GEE model with an interaction term provides robust standard error estimates. Linear mixed effects models were used to evaluate Models 2--4, with random effects to account for family structures. All FG analyses were adjusted for age, sex, BMI and the genetic principal components associated with FG at *p*\<0.05.

Meta-analysis {#sec008}
-------------

For both traits, we obtained summary statistics of association from each cohort and then conducted fixed-effect meta-analysis to combine the results. For each trait (incident T2D and FG), we meta-analyzed the results across the cohorts using inverse variance weighting, in EA and AA separately. We defined a potential interaction effect between a locus and smoking if at least one of the following criteria was met: 1) significant SNP-by-smoking interaction; 2) significant joint 2-degree-of-freedom test of interaction and main effect, excluding SNPs with significant main effects; or 3) significant SNP effect in only one smoking stratum (never or ever smokers). In the discovery stage, significance was defined as p\<10^−3^; we selected all SNPs significant for at least one of these 3 criteria as candidate SNPs. Candidate SNPs were then carried forward for replication in the cohorts of the CHARGE Consortium. We performed meta-analyses with summary statistics from the discovery and replication stages, defining significance as *p* \< 1×10^−7^ for at least one of the 3 criteria above. We selected this significance threshold to conservatively account for multiple hypothesis-testing, since *p* \< 2×10^−6^ is commonly used for studies with the 50,000-SNP IBC genotyping array \[[@pone.0230815.ref040], [@pone.0230815.ref041]\] and we performed a total of 20 tests (5×2×2), comprised of 5 models (main effect, interaction effect, joint effect, and 2 smoking stratified analyses) for 2 traits in 2 ancestry groups for each variant.

Power calculations {#sec009}
------------------

Power analyses were performed for a significance level of α = 1x10-7 to detect a potential interaction effect on both T2D and FG. For T2D, we approximated the power analysis to detect potential interaction with logistic regression. Under the assumption that the effect size for interaction is similar to the effect size of the main SNP effect, the sample sizes of 4,040 EA cases and 717 AA cases enabled 80% power to detect an odds ratio (OR) of 1.39 in EA and 1.76 in AA, using an unmatched population-based case-control design under an additive genetic model and assuming MAF = 0.3 with 10% T2D prevalence and 30% smoking prevalence. For FG, the sample sizes of 58,783 EA and 17,675 AA enabled 80% power to detect SNPs with R^2^~GE~ ≥ 0.06% EA and ≥ 0.2% AA for SNP\*interaction effect in interaction testing, using an additive genetic model and assuming variants with R^2^~G~ = 0.1%

Conditional analysis {#sec010}
--------------------

We performed conditional analyses for the two significant variants identified in *TCF7L2* in the T2D analysis. In each corhort, we ran the joint (Model 1) and main effect only models (Model 2) described above for rs4132670 conditioned on the most significant variant, rs12243326. The cohort-level conditional analyses were meta-analyzed to obtain overall summary statistics.

Locus characterization {#sec011}
----------------------

We queried the National Human Genome Research Institute (NHGR)--European Bioinformatics Institute (EBI) GWAS Catalog for any published trait associations with SNPs achieveing GEWIS significance in this study \[[@pone.0230815.ref042]\]. We also examined the overlap between these SNPs and genomic annotation using HaploReg \[[@pone.0230815.ref043]\], which collects information from multiple functional annotation resources and reports information about queried SNPs such as genomic position, protein-coding impact, available expression quantitative trait locus (eQTL) data, overlap with known transcription factor binding sites or predicted transcription factor binding motifs, and overlap with DNAse hypersensitivity sites or histone marks associated with promoters and enhancers. In addition, we queried each GEWIS-significant SNP in RegulomeDB \[[@pone.0230815.ref044]\], a database of known and predicted regulatory elements in human intergenic regions, and in the Genotype-Tissue Expression project (GTEx) portal to obtain additional eQTL data \[[@pone.0230815.ref045]\].

Results {#sec012}
=======

Incident T2D {#sec013}
------------

A total of 371 SNPs met the *p*\<10^−3^ threshold for incident T2D in discovery stage analyses and were carried forward to the replication stage. Of these, 171 were identified among EA individuals and 200 were identified in AA individuals; no SNP was identified in both subgroups (**[S2 Table](#pone.0230815.s002){ref-type="supplementary-material"}**).

In meta-analysis of discovery and replication estimates, five SNPs were significant for potential interaction at *p*\<1×10^−7^ by at least one criterion, and two of these were significant by two criteria (**[Table 1](#pone.0230815.t001){ref-type="table"}**). Two SNPs had significant joint effects in the overall model and significant main effects in only one smoking stratum in stratified analyses: rs140637 (*FBN1* on chromosome 15, MAF = 0.13) among AA smokers and rs1444261 (closest gene *C2orf63* on chromosome 2, MAF = 0.05) among EA nonsmokers. Among AA participants, rs140637 in *FBN1* was consistently associated with lower T2D risk among smokers only. In the discovery, replication, and combined stage meta-analyses, the per-allele HR for T2D was 0.34 (95% CI = 0.23, 0.51, *p* = 8.8 x 10^−8^), 0.39 (95% CI = 0.20, 0.76, *p* = 5.3 x 10^−3^), and 0.34 (95% CI = 0.24, 0.49, *p* = 2.9 x 10^−9^), respectively. For rs1444261 near *C2orf63*, in the discovery stage, the per-allele hazard ratio (HR) for T2D was 0.64 (95% CI = 0.51, 0.82, *p* = 3.7 x 10^−4^) among never smokers, but the direction of effect reversed in the replication stage (HR 1.24, 95% CI = 1.18, 1.29, *p* = 3.1 x 10^−21^) and overall meta-analysis (HR 1.21, 95% CI = 1.16, 1.26, *p* = 5.1 x 10^−18^).

10.1371/journal.pone.0230815.t001

###### Results of discovery (D), replication (R), and combined (D+R) stage meta-analyses of genotype-by-ever smoking for incident type 2 diabetes (T2D).

Bold text indicates a significant potential interaction effect between a SNP and smoking by at least one of the following criteria: (1) significant SNP-by-smoking interaction (p_int); (2) significant joint 2 degree of freedom test of interaction and main effect, excluding SNPs with significant main effects (p_joint); or (3) significant SNP effect in only one smoking stratum (ever or never smokers, p_ever or p_never). No locus met D+R significance at *p*\<10^−7^ for association with baseline fasting glucose.

![](pone.0230815.t001){#pone.0230815.t001g}

  Trait   Race   SNP          CHr       Position    A1        A2            Freq1       Closest gene   Stage       beta_main     p_main    beta_int    p_int     p_joint       beta_ever   p_ever        beta_never   p_never
  ------- ------ ------------ --------- ----------- --------- ------------- ----------- -------------- ----------- ------------- --------- ----------- --------- ------------- ----------- ------------- ------------ -------------
  T2D     EA     rs1444261    2         55207970    T         C                         *C2orf63*      D           -2.00E-01     1.8E-02   3.30E-01    5.3E-02   2.8E-03       8.00E-02    4.8E-01       -4.40E-01    **3.7E-04**
  0.95    R      3.90E-03     8.4E-01   -1.87E-01   1.6E-04   1.6E-23       -1.64E-02   7.1E-01        2.11E-01    3.1E-21                                                                                            
          D+R    -6.80E-03    7.3E-01   -1.47E-01   2.0E-03   **2.5E-20**   -2.44E-02   5.5E-01        1.90E-01    **5.1E-18**                                                                                        
  T2D     EA     rs4132670    10        114757761   A         G                         *TCF7L2*       D           2.30E-01      4.0E-07   6.90E-03    9.4E-01   2.8E-06       2.41E-01    **1.5E-05**   2.23E-01     3.5E-03
  0.30    R      5.30E-02     5.4E-09   2.27E-02    3.1E-01   2.7E-09       9.89E-02    9.9E-07        4.15E-02    4.5E-05                                                                                            
          D+R    6.00E-02     1.7E-11   2.18E-02    3.2E-01   1.3E-12       1.16E-01    **9.6E-10**    4.48E-02    8.9E-06                                                                                            
  T2D     EA     rs12243326   10        114778805   T         C                         *TCF7L2*       D           -2.54E-01     3.7E-08   -1.24E-02   8.9E-01   2.3E-07       -2.71E-01   **1.5E-06**   -2.21E-01    4.9E-03
  0.74    R      -4.84E-02    2.6E-07   -1.50E-02   5.1E-01   3.5E-07       -8.45E-02   4.4E-05        -3.80E-02   3.1E-04                                                                                            
          D+R    -5.67E-02    7.1E-10   -1.48E-02   5.0E-01   1.3E-10       -1.07E-01   **3.2E-08**    -4.13E-02   7.5E-05                                                                                            
  T2D     AA     rs1801232    10        16910918    T         G                         *CUBN*         D           7.77E-01      8.2E-06   6.95E-01    1.1E-01   **4.7E-07**   9.67E-01    **5.0E-07**   2.72E-01     4.9E-01
  0.12    R      1.20E-03     9.9E-01   1.39E+00    6.4E-02   1.7E-01       1.29E+00    4.2E-02        -3.12E-01   4.6E-01                                                                                            
          D+R    6.24E-01     6.4E-05   8.64E-01    2.0E-02   1.3E-07       1.02E+00    **5.5E-08**    9.70E-03    9.7E-01                                                                                            
  T2D     AA     rs140637     15        46554147    A         G                         *FBN1*         D           -6.38E-01     1.4E-03   -1.27E+00   6.0E-03   **2.8E-06**   -1.07E+00   **8.8E-08**   1.25E-01     7.6E-01
  0.87    R      -5.27E-01    1.6E-02   -7.25E-01   1.3E-01   6.9E-03       -9.41E-01   5.3E-03        5.40E-03    9.9E-01                                                                                            
          D+R    -5.88E-01    6.7E-05   -1.01E+00   2.2E-03   **2.2E-08**   -1.07E+00   **2.9E-09**    5.49E-02    8.3E-01                                                                                            

Abbreviations: A: allele, AA: African-American, Chr: chromosome, EA: European-American. Freq1: allele frequency of the coded effect allele (A1).

Three additional SNPs were significant by one criterion only, namely, significant main effect only among smokers in stratified analyses. Among EA smokers, these included rs4132670 (MAF = 0.30) and rs12243326 (MAF = 0.26), both in the well-described T2D-associated gene *TCF7L2*. Among AA smokers, rs1801232, a missense SNP in *CUBN* on chromosome 10 (MAF = 0.12), exhibited a significant main effect (**[S1 Fig](#pone.0230815.s005){ref-type="supplementary-material"}**). We observed the largest effect size for potential interaction at this *CUBN* missense variant, where the per-allele hazard ratio for T2D was 2.78 (95% CI = 1.92, 4.03, *p* = 5.5 x 10^−8^) among smokers and 1.01 (95% CI = 0.58, 1.77, *p* = 0.97) among non-smokers (*p*~*joint*~ = 1.3 x 10^−7^).

We provide regional plots for rs1224336 in *TCF7L2* in **[Fig 1](#pone.0230815.g001){ref-type="fig"}** because the discovery stage, replication stage, and combined meta-analysis showed chip-wide significance for joint effect and main effect in smokers among EA participants. Among smokers and non-smokers, the per-allele HR for T2D in the discovery plus replication meta-analysis was 0.90 (95% CI = 0.86, 0.93, *p* = 3.2 x 10^−8^) and 0.96 (95% CI = 0.94, 0.98, *p* = 7.5 x 10^−5^), respectively. In analyses conditioned on rs12243326, rs4132670 (r^2^ = 0.72 and D\' = 0.95) was no longer significantly associated with main effect with T2D (all *p*\>0.4).

![Regional plots for the association of rs1224336 in *TCF7L2* with T2D.](pone.0230815.g001){#pone.0230815.g001}

Fasting glucose {#sec014}
---------------

In the discovery stage analysis for baseline FG among 23,189 participants, we observed 343 SNPs meeting the significance threshold of p\<10^−3^ in at least one of the three planned strategies for potential interaction: 175 among EA participants and 168 among AA participants. Again, no locus was identified in both ancestral subgroups (**[S3 Table](#pone.0230815.s003){ref-type="supplementary-material"}**). Meta-analysis identified rs4132670 in *TCF7L2* (MAF = 0.30) as the most significant variant for the joint effect analysis in EA participants only (*p =* 4.6 x10^-8^), but it did not meet the criteria for potential interaction because its main effect association was also significant (*p* = 2.8 ×10^−10^)

Locus characterization {#sec015}
----------------------

Of the five SNPs at four loci achieving statistical significance in the GEWIS analyses (*TCF7L2*, *CUBN*, *FBN1*, and near *C2orf63*), only rs12243326, an intronic variant in *TCF7L2*, has trait associations in the NHGRI-EBI GWAS Catalog, with the glycemic traits of 2-hour glucose challenge, fasting insulin, FG, and BMI interaction on FG. Of the five SNPs at four loci achieving statistical significance in the GEWIS analyses (*TCF7L2*, *CUBN*, *FBN1*, and near *C2orf63*), only the missense *CUBN* SNP is a nonsynonymous variant. All five GEWIS-significant SNPs overlap with at least one promoter or enhancer regulatory mark in at least one tissue with relevance to diabetes, including brain, muscle, gastrointestinal tract, pancreas, adipose, and liver (**[S4 Table](#pone.0230815.s004){ref-type="supplementary-material"}**). SNPs at three of the four loci (*C2orf63*, *TCF7L2*, and *CUBN*) had eQTL associations, and SNPs at all four loci overlap with either a DNA-binding site or alter a predicted DNA-binding motif (**[S4 Table](#pone.0230815.s004){ref-type="supplementary-material"}**).

Discussion {#sec016}
==========

Using data from 61,164 participants from 19 cohort studies, we performed two GEWIS to identify potential SNP-by-smoking interactions in the risk of T2D and baseline FG. We identified potential interactions between smoking status and five SNPs at or near four genes (*TCF7L2*, *CUBN*, *C2orf63 (closest gene)*, and *FBN1*) on the risk of incident T2D in EA or AA participants. We identified no significant SNP-smoking interactions for FG.

The relationship between smoking and T2D is complex and likely results from both confounding and true causal relationships \[[@pone.0230815.ref046]\]. Smokers are less likely to be physically active \[[@pone.0230815.ref047]\] and more likely to have unhealthier dietary intake \[[@pone.0230815.ref048], [@pone.0230815.ref049]\]. Still, a meta-analysis of 25 prospective studies by Willi found that smokers had a risk ratio for incident T2D of 1.44 (95% CI 1.31, 1.58) over 5 to 30 years of follow-up after adjustment, when possible, for BMI, physical activity, and other potential confounders. Individuals with the greatest smoking exposure had the greatest T2D risk \[[@pone.0230815.ref005]\]. Moreover, experimental data suggest plausible causal pathways between smoking and T2D. First, smoking generates reactive oxygen species (ROS) \[[@pone.0230815.ref050]\], which decrease *in vitro* insulin-mediated glucose transport \[[@pone.0230815.ref011]\]. Second, smoking stimulates the sympathetic system and cortisol release, increasing central obesity and insulin resistance \[[@pone.0230815.ref012]--[@pone.0230815.ref014]\]. Nicotine may mediate these pathways, as it increases insulin resistance \[[@pone.0230815.ref015]--[@pone.0230815.ref018]\], possibly through increased ROS production and TNF-α expression \[[@pone.0230815.ref018]\]. Nicotine also decreases insulin secretion from pancreatic β-cells \[[@pone.0230815.ref019]\], and fetal and neonatal exposure to nicotine results in β-cell dysfunction and apoptosis \[[@pone.0230815.ref020],[@pone.0230815.ref021]\]. GEWIS might help elucidate additional biological pathways to explain the relationship between smoking and T2D. A linkage disequilibrium regression score study of 276 genetic correlations among 24 traits found no genetic correlation between smoking status and either T2D or FG \[[@pone.0230815.ref051]\], but one small study has reported that smoking status accounted for 22% of the gene-environment variance in β-cell function, as measured by the homeostatic model assessment (HOMA-β) \[[@pone.0230815.ref052]\].

We observed the largest potential interaction effect size at the missense SNP rs1801232 in the *CUBN* gene in individuals of African ancestry, where the per-allele hazard ratio for T2D was 2.78 (95% CI = 1.92, 4.03, *p* = 5.5 x 10^−8^) among smokers and 1.01 (95% CI = 0.58, 1.77, *p* = 0.97) among non-smokers (*p*~*joint*~ = 1.3 x 10^−7^). Cubilin is a component of the vitamin B12-intrinsic factor complex receptor in the ileal mucosa \[[@pone.0230815.ref053]\], and it is expressed in the apical brush border of the renal proximal tubule, where it participates in receptor-mediated endocytosis of low-molecular-weight proteins \[[@pone.0230815.ref054]\]. Defects in the *CUBN* gene have been associated with both vitamin B12 deficiency and proteinuria, and the absence of cubilin results in the autosomal recessive condition Imerslund-Gräsbeck syndrome, characterized by B12 malabsorption and variable levels of proteinuria from impaired renal protein reabsorption \[[@pone.0230815.ref055]\]. Mice heterozygous for *CUBN* deletion have increased albuminuria and decreased levels of blood albumin and high-density lipoprotein (HDL) cholesterol \[[@pone.0230815.ref056]\]. The CKDGen consortium meta-analysis identified a missense SNP in *CUBN* (rs18801239) associated with urinary albumin/creatinine ratio and clinical microalbuminuria in the general population, an association replicated in an AA cohort with type 1 diabetes \[[@pone.0230815.ref057]\] and later in the Framingham Offspring Study \[[@pone.0230815.ref058]\]. This SNP appears independent from the *CUBN* SNP identified in the present analysis: in conditional analyses on rs18801239 in the discovery cohort, we found that rs18801232 remained significantly associated with incident T2D among AA smokers only. These *CUBN* observations point to plausible mechanisms, namely depressed levels of vitamin B12 and HDL cholesterol, through which smoking might interact with cubilin to cause T2D. Cigarette smoking impairs cubilin-mediated renal protein reabsorption through cadmium and other contaminants, which form complexes with proteins that have high affinity for cubilin and accumulate in the proximal tubule \[[@pone.0230815.ref059]\]. A mendelian randomization study found an association between a genetic instrument for low vitamin B12 levels (including one *CUBN* variant) and higher fasting glucose levels and lower pancreatic beta-cell secretory function, as measured by HOMA-β, but not with higher odds of T2D \[[@pone.0230815.ref060]\]. Mendelian randomization studies have been inconsistent in whether genetic instruments for low HDL are associated with increased T2D risk \[[@pone.0230815.ref061]--[@pone.0230815.ref064]\]. Whether *CUBN* defects and smoking interact to cause T2D through these or other mechanisms merits further investigation.

We observed more modest potential interaction effects at four other SNPs. Among AA participants, one SNP in *FBN1* was associated with T2D only in smokers. The glycoprotein fibrillin-1 is a component of microfibrils in the extracellular matrix, which contribute to the elasticity of skin, blood vessels, and other tissues. Variants in *FBN1* are associated with Marfan syndrome, an autosomal dominant connective tissue disorder characterized by ocular, skeletal, and cardiovascular abnormalities, including aortic dilatation and cardiac valve regurgitation \[[@pone.0230815.ref065]\]. Among EA participants, one locus near *C2orf63*, which encodes a neurite outgrowth inhibitor, was associated with T2D only in never smokers. This observation may suggest either a protective role of smoking in the association of *C2orf63* and T2D or an *C2orf63*-T2D association otherwise obscured by the association between smoking and T2D. The two remaining loci we identified were in *TCF7L2*, a gene whose well-established association with T2D was first identified in 2006 and which remains the locus with the largest effect on T2D risk \[[@pone.0230815.ref066]--[@pone.0230815.ref068]\]. Variants in *TCF7L2* are associated with decreased pancreatic beta-cell function \[[@pone.0230815.ref069],[@pone.0230815.ref070]\] and incretin sensitivity \[[@pone.0230815.ref071]\], and their association with increased proinsulin levels suggest defects in insulin processing and secretion \[[@pone.0230815.ref072]\]. Experimental models support the role of *TCF7L2* variants in developmental beta cell proliferation, proinsulin processing, and insulin vesicle docking \[[@pone.0230815.ref073]\].

Examination of the functional genomic annotation of the GEWIS-significant SNPs generates novel biological hypotheses. For example, allele-specific differential gene expression impacting glucose homeostasis in smokers versus non-smokers could explain the observed potential gene-smoking interaction. A mechanism of interaction involving gene expression would be consistent with all five statistically-significant SNPs being associated with regulatory histone marks. Even the missense variant in the *CUBN* gene overlaps with regulatory annotation in numerous tissues, including active enhancer histone marks in muscle, adipose, pancreas, and liver, and tags multiple DNA-binding protein sites. Similarly, the intergenic SNP at the *C2orf63* locus overlaps with both active enhancer and promoter histone marks from brain/neural tissues. The intronic variant in the *FBN1* gene overlaps with promoter and/or active enhancer marks in brain, muscle, adipose, gastrointestinal tract, or pancreatic tissues. Finally, each of the two intronic SNPs at the *TCF7L2* locus has a slightly different pattern of regulatory annotation. In addition, the pattern of regulatory marks overlapping the two *TCF7L2* SNPs identified in this study differs from the regulatory annotation related to the lead *TCF7L2* SNP associated in T2D case-control GWAS, suggesting multiple, potentially distinct regulatory mechanisms underlying T2D in smokers and non-smokers. Further work is required to illuminate how smoking might modify biologic pathways, including gene regulation, and may suggest novel targets for diabetes therapy.

Prior studies of gene-smoking interaction for T2D risk have used a candidate gene approach, focusing on loci associated either with smoking behavior, such as *CYP2A6* \[[@pone.0230815.ref074]\] or the *nicotinic acetylcholine receptor gene* (*CHRNA4*) \[[@pone.0230815.ref075]\], or with T2D and other metabolic traits \[[@pone.0230815.ref076]\], including *HNF1A* \[[@pone.0230815.ref077]\] and *APOC3* \[[@pone.0230815.ref078]\]. Our analyses did not replicate the findings of these small candidate-gene studies at our predefined genome-wide significance thresholds, highlighting unique contributions using unbiased GEWIS approaches. Limitations of our study include the dichotomous categorization of the smoking exposure (ever vs. never), which likely masks some of the effect of smoking dose and duration on our outcomes of interest. Nonetheless, similar approaches have successfully identified gene-smoking interactions for traits such as blood pressure \[[@pone.0230815.ref079]\], pulmonary function \[[@pone.0230815.ref080]\], and BMI \[[@pone.0230815.ref081]\]. Second, a locus identified by the inclusion of a significant joint test as one criterion for potential locus-smoking interaction may actually have a significant main effect, not a significant interaction with smoking, if the inclusion of smoking in the model explained residual variability in the outcome and increased power to detect main effects. To limit the impact of this misclassification, we excluded SNPs with significant main effects from eligibility for this criterion. Third, although we used data from about 75,000 individuals across the CHARGE Consortium Gene-Lifestyle Interactions Working Group to replicate our discovery analyses, data from larger cohorts such as the UK Biobank and Million Veteran Program now exist and might provide future opportunity for additional replication. Fourth, our discovery analyses only leveraged genotype data from the IBC array available from the CARe Consortium; the use of increasingly available sequencing data from large cohort studies might enable the detection of rare variants that mediate the relationship between smoking and glycemic traits. Fifth, the lack of adequate numbers of T2D cases in all sex/ancestry groups impeded adjustment for sex in some models. It is unknown whether this lack of sex adjustment biased the results and, if so, the direction and magnitude of effect. Larger studies in individuals of non-European ancestry are needed to address this limitation.

Conclusions {#sec017}
===========

We have demonstrated the feasibility and utility of GEWIS to identify potential gene-smoking interactions in T2D risk. Future mechanistic study of the loci identified may help untangle the complex relationship between the dual public health threats of T2D and smoking.
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Reviewer \#1: This is a paper investigating smoking by genotype interaction in incident T2DM and FG using data from two well-known consortia. The paper is well written and addresses a relevant topic.

There is something about this manuscript that puzzles me. In line 146-158 the authors briefly describe the cohorts from the two consortia contributing to this study, referring to Supplemental Table 1. According to the text, data from 5 cohorts were used for the discovery stage, and data from 14 cohorts in the replication stage.

In Supplemental Table 1, however, I noticed that for the replication stage, only 4 out of 14 cohorts contribute to the GEWIS for incident type 2 diabetes (row 12 in Supplemental Table 1: 10 do not have data on incident T2DM). In addition, only 12 cohorts contribute to the GEWIS for fasting glucose (2 do not have glucose measurements). This seemed odd to me, because the significant interactions observed in this study are for the analyses concerning incident T2DM, not for fasting glucose\.....

The authors do not acknowledge this fact (4 instead of 14 cohorts for incident T2D in replications stage) anywhere in the manuscript. There may have been a mistake, an old version of Supplemental Table 1 may have been uploaded, or the results of the replications stage are really based on only 4 resp. 12 cohorts. If the latter is the case, then the authors should describe this early in the manuscript, because it puts the results in a completely different perspective. Now the authors only refer to their small number of incident T2D cases in the context of not being able to adjust for sex (line 197 and 422).

Have the authors performed a power analyses before conducting the study? If so, please include.

In the cohort description it would really help to also list the number of incident cases of type 2 diabetes for the discovery and replication stage cohorts. It would also be informative to include the number of cohorts with family structures in discovery and replications stages.

Why did the authors include the results from both the discovery and replication estimates in the meta-analysis, why not restrict this to replication results only?

In the discussion a paragraph needs to be included about how the results and their meaning/interpretation are affected by the fact that sex could not be taken into account in most analyses.

Minor comments

Regulome DB is not included in the methods section, but is included in Suppl. T4

In line 269 please prove the 95% CI

In line 302 is reference is made to Table 1, but glucose results are not included in this Table.

For example, the refs 24 and 25 in line 337 are incorrect (refs 24 and 25 in the list (p. 23) do not cover the topic of B-cell dysfunction and apoptosis)

Reviewer \#2: Wu et al. have performed an array-wide association study for gene-smoking interactions on fasting glucose and incident T2D. They do not identify significant interaction effects, but report some novel significant associations when testing joint associations with SNP main effect and interaction, and associations that reach the significance in one stratum (smokers or ever smokers) but not the other. The paper includes some novel findings, but I have concerns about how the findings have been reported.

1\. Defining interaction as a SNP main effect that is significant in only one smoking stratum (never or ever smokers) is misleading, as this does not give any information of how the SNP effect differs between the strata, i.e. the interaction effect. Please do not define these findings as interaction effects, but use appropriate wording.

2\. It is also misleading to define the joint association of SNP main effect and interaction effect as an interaction. The identification of a locus in the joint test but not in a SNP main effect test could be due to an interaction effect, but could also be simply due to the adjustment of the model for smoking which increases power by explaining some of the residual variability in the outcome trait.

3\. Lines 214-215: "...excluding SNPs with significant main effects..." What P value was considered a significant SNP main effect? Considering that the TCF7L2 locus is the locus with the strongest known main effect on T2D risk, it is surprising that TCF7L2 was not excluded at this stage.

4\. Please do not only report results for single SNPs but indicate clearly when the SNPs represent independent loci, based on distance and/or LD threshold values, or conditional analyses.

5\. Lines 267-271: It is not possible that a SNP has a significant T2D-risk decreasing effect HR=0.64 in the discovery stage and a significant risk-increasing effect in the replication stage with HR=1.19, and the combined meta-analysis P value is still significant with HR=1.17. Please double-check this result. Due to the opposite direction of effect between the discovery and replication stages, the combined P value should be close to HR=1.

6\. Line 269: "CI=XXX, XXX", please add the missing numbers here.

7\. Line 355-356: Important to clarify whether the CKDGen consortium meta-analysis identified the same CUBN missense SNP as identified in the present study.

8\. Line 420: "such as" words are out of place here.

9\. Lines 426-428: The conclusions are not justified by the data. This paragraph needs to be revised to be consistent with the findings. It should be clearly stated that no significant interaction effects were found. Rather, the authors found some loci that showed significant joint test associations for SNP main effect and interaction, and associations that were significant in one smoking stratum but not the other. Future studies with larger sample sizes are required to provide evidence of interaction for these loci.

10\. TABLE 1: It is critical to indicate which allele is the effect allele, and to add effect allele frequency in the table.

11\. FIGURE 1d: The association pattern looks strange. What was the sample size and imputation quality for this variant? What reference panel was used for the LD?

Reviewer \#3: Wu et al. describe results from Gene x Smoking interactions analyses for type 2 diabetes (T2D) and fasting glucose (FG).

The study is based on a 2-stage design, including a discovery and replication stage. The discovery stage consists of 5 cohorts from the CARe consortium (N\~24,000). The discovery samples were genotyped on the Custom ITMAT-Broad-CARe (IBC) genotyping array that contains \~50K SNPs selected for their impact on cardiovascular diseases. The replication stage consists of data from the CHARGE consortium (N\~75,000). Both stages involve individuals of European and African ancestry (EA and AA, respectively). All analyses were stratified by ancestry status. Smoking was defined by a binary variable SMK that compares ever and never smokers.

For each ancestry group, each trait and each of the two stages, the authors applied four regression models: (i) An interaction model that includes SNP, SMK, SNPxSMK and other covariates, (ii) a main effect model (excluding the interaction term), (iii) a main effect model that was restricted to ever smokers and (iv) a main effect model that was restricted to never smokers. For each stage, the authors conducted fixed-effect meta-analysis to combine cohort-specific results. In addition, the results of the individual stages were meta-analysed.

They selected variants from discovery that showed (a) significant SNP x Smk interaction (Pint \< 1e-3), (b) significant joint main+interaction effect (Pjoint \<1e-3, excluding those with significant main effects Pmain \<1e-3), or (c) significant subgroup effects (P\<1e-3, excluding those that show an effect in the other subgroup as well). They selected 371 variants from discovery, which were then followed-up in a combined discovery+replication stage. They identified 6 SNPs for T2D with P\<1e-7 for at least one of the three approaches (a)-(c). They did not identify any variant for FG. The identified variants are likely candidates for SNP x Smk interactions for T2D.

The study is informative and adds to previous work. It provides additional insight into the biological and genetic underpinning of T2D. The results will be of interest for those studying diabetes and related traits. I only have some minor comments:

1\. Table 1 shows results for the 6 variants. It seems that only three of the 6 variants have nominal significant interaction P values. I think this deserves some discussion as to how much one can trust those interactions. Also, I would find it helpful to add P values for the test for difference between beta_never and beta_ever that may help the interpretation of these findings. The abstract says that the findings "provide evidence" for interactions. Personally, I would tone down on that a little bit. No doubt, the identified loci are likely candidates for interactions but not necessarily proven (as mentioned above, P int is not even nominal significant for three of the 6 variants).

2\. Have the authors thought of testing the interaction for known main effect T2D and FG variants?

3\. Page 3, line 100: "cohorts"

4\. Page 11, line 269: CI's are missing
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Dear Dr. Vassy:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr David Meyre

Academic Editor
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